{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T12:48:30Z","timestamp":1789735710406,"version":"4.0.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CD200R is a checkpoint inhibitory receptor central to the pathogenesis of inflammatory skin disease. Here we describe the development and phase 1 clinical study (NCT03750643) of ucenprubart, a CD200R agonist antibody to downregulate immune system inflammation. Preclinical studies find ucenprubart inhibiting Fc\u03b3 receptor-induced cytokine secretion from myeloid cells in vitro and demonstrating efficacy in a mouse contact hypersensitivity model. The randomized, placebo-controlled, NCT03750643 trial assesses safety and pharmacokinetics in healthy subjects, and efficacy in atopic dermatitis patients. The primary efficacy outcome is the proportion of patients achieving Validated Investigator\u2019s Global Assessment for Atopic Dermatitis (vIGA-AD) 0 or 1 with \u22652-point improvement from baseline at week 12. Secondary outcomes are proportions of patients achieving the primary outcome and mean changes in Eczema Area and Severity Index (EASI) and SCORing Atopic Dermatitis (SCORAD) across weeks 1 through 12, and cutoffs at week 12. Sixty-two healthy participants and 40 patients are enrolled. No serious adverse events or discontinuations due to adverse events is seen with ucenprubart. The primary endpoint is not met; however, overall improvements are observed in EASI-75 and SCORAD through 12 weeks. CD200R may be a promising therapeutic target for treating autoimmune disease, including inflammatory skin diseases.<\/jats:p>","DOI":"10.1038\/s41467-025-59147-w","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T03:58:50Z","timestamp":1746071930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical study"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3142-9675","authenticated-orcid":false,"given":"Anja","family":"Koester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derrick R.","family":"Witcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Demarest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Werle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Malherbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Poorbaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Glasebrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1039-6080","authenticated-orcid":false,"given":"Christoph","family":"Preuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gourab","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Knorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Manner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipak","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Schmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Klekotka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Nirula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"59147_CR1","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.4049\/jimmunol.171.6.3034","volume":"171","author":"GJ Wright","year":"2003","unstructured":"Wright, G. J. et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J. Immunol. 171, 3034\u20133046 (2003).","journal-title":"J. Immunol."},{"key":"59147_CR2","doi-asserted-by":"publisher","first-page":"e35466","DOI":"10.1371\/journal.pone.0035466","volume":"7","author":"S Caserta","year":"2012","unstructured":"Caserta, S. et al. Chronic infection drives expression of the inhibitory receptor CD200R, and its ligand CD200, by mouse and human CD4 T cells. PloS ONE 7, e35466 (2012).","journal-title":"PloS ONE"},{"key":"59147_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1365-2249.2010.04227.x","volume":"162","author":"E Simelyte","year":"2010","unstructured":"Simelyte, E., Alzabin, S., Boudakov, I. & Williams, R. CD200R1 regulates the severity of arthritis but has minimal impact on the adaptive immune response. Clin. Exp. Immunol. 162, 163\u2013168 (2010).","journal-title":"Clin. Exp. Immunol."},{"key":"59147_CR4","doi-asserted-by":"publisher","first-page":"e0146681","DOI":"10.1371\/journal.pone.0146681","volume":"11","author":"Z Chen","year":"2016","unstructured":"Chen, Z., Yu, K., Zhu, F. & Gorczynski, R. Over-expression of CD200 protects mice from dextran sodium sulfate induced colitis. PloS ONE 11, e0146681 (2016).","journal-title":"PloS ONE"},{"key":"59147_CR5","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1182\/blood-2006-06-029355","volume":"108","author":"J Moreaux","year":"2006","unstructured":"Moreaux, J. et al. CD200 is a new prognostic factor in multiple myeloma. Blood 108, 4194\u20134197 (2006).","journal-title":"Blood"},{"key":"59147_CR6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/sj.leu.2404559","volume":"21","author":"A Tonks","year":"2007","unstructured":"Tonks, A. et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 21, 566\u2013568 (2007).","journal-title":"Leukemia"},{"key":"59147_CR7","doi-asserted-by":"publisher","first-page":"e000189","DOI":"10.1136\/jitc-2019-000189","volume":"8","author":"F Choueiry","year":"2020","unstructured":"Choueiry, F. et al. CD200 promotes immunosuppression in the pancreatic tumor microenvironment. J. Immunother. Cancer 8, e000189 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"59147_CR8","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1007\/s00262-020-02589-6","volume":"69","author":"C Xin","year":"2020","unstructured":"Xin, C. et al. CD200 is overexpressed in neuroblastoma and regulates tumor immune microenvironment. Cancer Immunol. Immunother. 69, 2333\u20132343 (2020).","journal-title":"Cancer Immunol. Immunother."},{"key":"59147_CR9","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-3-030-35582-1_8","volume":"1223","author":"JQ Liu","year":"2020","unstructured":"Liu, J. Q. et al. CD200-CD200R pathway in the regulation of tumor immune microenvironment and immunotherapy. Adv. Exp. Med. Biol. 1223, 155\u2013165 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"59147_CR10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150750","volume":"132","author":"HJ Morgan","year":"2022","unstructured":"Morgan, H. J. et al. CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis. J. Clin. Invest. 132, e150750 (2022).","journal-title":"J. Clin. Invest."},{"key":"59147_CR11","doi-asserted-by":"publisher","first-page":"6052","DOI":"10.1128\/JVI.79.10.6052-6067.2005","volume":"79","author":"CM Cameron","year":"2005","unstructured":"Cameron, C. M., Barrett, J. W., Liu, L., Lucas, A. R. & McFadden, G. Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation in vivo. J. Virol. 79, 6052\u20136067 (2005).","journal-title":"J. Virol."},{"key":"59147_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/B978-0-12-800100-4.00005-2","volume":"121","author":"CA Vaine","year":"2014","unstructured":"Vaine, C. A. & Soberman, R. J. The CD200-CD200R1 inhibitory signaling pathway: immune regulation and host-pathogen interactions. Adv. Immunol. 121, 191\u2013211 (2014).","journal-title":"Adv. Immunol."},{"key":"59147_CR13","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/all.13129","volume":"72","author":"LH Blom","year":"2017","unstructured":"Blom, L. H. et al. The immunoglobulin superfamily member CD200R identifies cells involved in type 2 immune responses. Allergy 72, 1081\u20131090 (2017).","journal-title":"Allergy"},{"key":"59147_CR14","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.jaci.2019.10.030","volume":"145","author":"S Mucha","year":"2020","unstructured":"Mucha, S. et al. Protein-coding variants contribute to the risk of atopic dermatitis and skin-specific gene expression. J. Allergy Clin. Immunol. 145, 1208\u20131218 (2020).","journal-title":"J. Allergy Clin. Immunol."},{"key":"59147_CR15","doi-asserted-by":"publisher","first-page":"e1008725","DOI":"10.1371\/journal.pgen.1008725","volume":"16","author":"MAR Ferreira","year":"2020","unstructured":"Ferreira, M. A. R. et al. Age-of-onset information helps identify 76 genetic variants associated with allergic disease. PLoS Genet. 16, e1008725 (2020).","journal-title":"PLoS Genet."},{"key":"59147_CR16","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1093\/hmg\/ddz175","volume":"28","author":"A Johansson","year":"2019","unstructured":"Johansson, A., Rask-Andersen, M., Karlsson, T. & Ek, W. E. Genome-wide association analysis of 350 000 Caucasians from the UK Biobank identifies novel loci for asthma, hay fever and eczema. Hum. Mol. Genet. 28, 4022\u20134041 (2019).","journal-title":"Hum. Mol. Genet."},{"key":"59147_CR17","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1523\/JNEUROSCI.4272-09.2010","volume":"30","author":"Y Liu","year":"2010","unstructured":"Liu, Y. et al. CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis. J. Neurosci. 30, 2025\u20132038 (2010).","journal-title":"J. Neurosci."},{"key":"59147_CR18","doi-asserted-by":"publisher","first-page":"580","DOI":"10.2353\/ajpath.2007.070272","volume":"171","author":"DA Copland","year":"2007","unstructured":"Copland, D. A. et al. Monoclonal antibody-mediated CD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis. Am. J. Pathol. 171, 580\u2013588 (2007).","journal-title":"Am. J. Pathol."},{"key":"59147_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.645699","volume":"12","author":"Y Zhai","year":"2021","unstructured":"Zhai, Y., Moosavi, R. & Chen, M. Immune checkpoints, a novel class of therapeutic targets for autoimmune diseases. Front. Immunol. 12, 645699 (2021).","journal-title":"Front. Immunol."},{"key":"59147_CR20","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1517\/14712598.2016.1152256","volume":"16","author":"JM Ryan","year":"2016","unstructured":"Ryan, J. M., Wasser, J. S., Adler, A. J. & Vella, A. T. Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: can we have our cake and eat it too? Expert Opin. Biol. Ther. 16, 655\u2013674 (2016).","journal-title":"Expert Opin. Biol. Ther."},{"key":"59147_CR21","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1080\/19420862.2018.1474996","volume":"10","author":"NS Alakhras","year":"2018","unstructured":"Alakhras, N. S. et al. Fc\u03b3RIIIa-dependent IFN-\u03b3 release in whole blood assay is predictive of therapeutic IgG1 antibodies safety. MAbs 10, 913\u2013921 (2018).","journal-title":"MAbs"},{"key":"59147_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101582","volume":"23","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Single-cell profiling reveals divergent, globally patterned immune responses in murine skin inflammation. iScience 23, 101582 (2020).","journal-title":"iScience"},{"key":"59147_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10252-x","volume":"7","author":"J Zeitvogel","year":"2017","unstructured":"Zeitvogel, J. et al. GATA3 regulates FLG and FLG2 expression in human primary keratinocytes. Sci. Rep. 7, 11847 (2017).","journal-title":"Sci. Rep."},{"key":"59147_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/JLB.2A0520-334R","volume":"111","author":"MI Pascoal Ramos","year":"2022","unstructured":"Pascoal Ramos, M. I. et al. CD200R1L is a functional evolutionary conserved activating receptor in human neutrophils. J. Leukoc. Biol. 111, 367\u2013377 (2022).","journal-title":"J. Leukoc. Biol."},{"key":"59147_CR25","unstructured":"DUPIXENT\u00ae (dupilumab) US prescribing information.). Regeneron Pharmaceuticals, Inc. (2022)."},{"key":"59147_CR26","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3389\/fimmu.2020.01768","volume":"11","author":"H He","year":"2020","unstructured":"He, H. et al. Tape-strip proteomic profiling of atopic dermatitis on dupilumab identifies minimally invasive biomarkers. Front. Immunol. 11, 1768 (2020).","journal-title":"Front. Immunol."},{"key":"59147_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","volume":"143","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky, E. et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J. Allergy Clin. Immunol. 143, 155\u2013172 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"59147_CR28","doi-asserted-by":"publisher","first-page":"a001651","DOI":"10.1101\/cshperspect.a001651","volume":"1","author":"T Lawrence","year":"2009","unstructured":"Lawrence, T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 1, a001651 (2009).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"59147_CR29","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri.2017.52","volume":"17","author":"SC Sun","year":"2017","unstructured":"Sun, S. C. The non-canonical NF-kappaB pathway in immunity and inflammation. Nat. Rev. Immunol. 17, 545\u2013558 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"59147_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu, T., Zhang, L., Joo, D. & Sun, S. C. NF-kappaB signaling in inflammation. Signal Transduct. Target Ther. 2, 17023 (2017).","journal-title":"Signal Transduct. Target Ther."},{"key":"59147_CR31","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1002\/art.37691","volume":"64","author":"A Yarilina","year":"2012","unstructured":"Yarilina, A., Xu, K., Chan, C. & Ivashkiv, L. B. Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum. 64, 3856\u20133866 (2012).","journal-title":"Arthritis Rheum."},{"key":"59147_CR32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/09546634.2016.1230173","volume":"28","author":"M Nakamura","year":"2017","unstructured":"Nakamura, M. et al. Eczema as an adverse effect of anti-TNF\u03b1 therapy in psoriasis and other Th1-mediated diseases: a review. J. Dermatol. Treat. 28, 237\u2013241 (2017).","journal-title":"J. Dermatol. Treat."},{"key":"59147_CR33","doi-asserted-by":"publisher","first-page":"R666","DOI":"10.1186\/ar1724","volume":"7","author":"M Flendrie","year":"2005","unstructured":"Flendrie, M. et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res. Ther. 7, R666\u2013R676 (2005).","journal-title":"Arthritis Res. Ther."},{"key":"59147_CR34","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40257-017-0296-7","volume":"18","author":"S Segaert","year":"2017","unstructured":"Segaert, S. & Hermans, C. Clinical signs, pathophysiology and management of cutaneous side effects of anti-tumor necrosis factor agents. Am. J. Clin. Dermatol 18, 771\u2013787 (2017).","journal-title":"Am. J. Clin. Dermatol"},{"key":"59147_CR35","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.3389\/fimmu.2018.02572","volume":"9","author":"S Ahmad","year":"2018","unstructured":"Ahmad, S. et al. The key role of TNF-TNFR2 interactions in the modulation of allergic inflammation: a review. Front. Immunol. 9, 2572 (2018).","journal-title":"Front. Immunol."},{"key":"59147_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25960-2","volume":"12","author":"JW Squair","year":"2021","unstructured":"Squair, J. W. et al. Confronting false discoveries in single-cell differential expression. Nat. Commun. 12, 5692 (2021).","journal-title":"Nat. Commun."},{"key":"59147_CR37","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"59147_CR38","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jaci.2016.06.010","volume":"138","author":"T Werfel","year":"2016","unstructured":"Werfel, T. et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J. Allergy Clin. Immunol. 138, 336\u2013349 (2016).","journal-title":"J. Allergy Clin. Immunol."},{"key":"59147_CR39","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan, S. M., Irvine, A. D. & Weidinger, S. Atopic dermatitis. Lancet 396, 345\u2013360 (2020).","journal-title":"Lancet"},{"key":"59147_CR40","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jaci.2020.04.062","volume":"147","author":"DS Bakker","year":"2021","unstructured":"Bakker, D. S. et al. Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers. J. Allergy Clin. Immunol. 147, 189\u2013198 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"59147_CR41","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41385-022-00524-9","volume":"15","author":"A Trompette","year":"2022","unstructured":"Trompette, A. et al. Gut-derived short-chain fatty acids modulate skin barrier integrity by promoting keratinocyte metabolism and differentiation. Mucosal Immunol. 15, 908\u2013926 (2022).","journal-title":"Mucosal Immunol."},{"key":"59147_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","volume":"143","author":"T Czarnowicki","year":"2019","unstructured":"Czarnowicki, T., He, H., Krueger, J. G. & Guttman-Yassky, E. Atopic dermatitis endotypes and implications for targeted therapeutics. J. Allergy Clin. Immunol. 143, 1\u201311 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"59147_CR43","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jaci.2017.03.023","volume":"140","author":"JL Thijs","year":"2017","unstructured":"Thijs, J. L. et al. Moving toward endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis. J. Allergy Clin. Immunol. 140, 730\u2013737 (2017).","journal-title":"J. Allergy Clin. Immunol."},{"key":"59147_CR44","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","volume":"156","author":"M Worm","year":"2020","unstructured":"Worm, M. et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 156, 131\u2013143 (2020).","journal-title":"JAMA Dermatol."},{"key":"59147_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abe2749","volume":"6","author":"C Bangert","year":"2021","unstructured":"Bangert, C. et al. Persistence of mature dendritic cells, TH2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL-4R\u03b1 blockade. Sci. Immunol. 6, eabe2749 (2021).","journal-title":"Sci. Immunol."},{"key":"59147_CR46","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0161-5890(93)90432-B","volume":"30","author":"S Angal","year":"1993","unstructured":"Angal, S. et al. A single amino acid substitution abolishes the heterogeneity of chimeric mouse\/human (IgG4) antibody. Mol. Immunol. 30, 105\u2013108 (1993).","journal-title":"Mol. Immunol."},{"key":"59147_CR47","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1006\/cimm.2000.1617","volume":"200","author":"D Xu","year":"2000","unstructured":"Xu, D. et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol. 200, 16\u201326 (2000).","journal-title":"Cell Immunol."},{"key":"59147_CR48","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172 (2019).","journal-title":"Nat. Immunol."},{"key":"59147_CR49","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41596-024-01020-z","volume":"19","author":"S Xu","year":"2024","unstructured":"Xu, S. et al. Using clusterProfiler to characterize multiomics data. Nat. Protoc. 19, 3292\u20133320 (2024).","journal-title":"Nat. Protoc."},{"key":"59147_CR50","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","volume":"70","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield, L. F. et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J. Am. Acad. Dermatol. 70, 338\u2013351 (2014).","journal-title":"J. Am. Acad. Dermatol."},{"key":"59147_CR51","unstructured":"ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT03750643 (2021)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59147-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59147-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59147-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T16:02:44Z","timestamp":1746460964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59147-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59147"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59147-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"assertion":[{"value":"6 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors with the exception of M.L. were employees, and many shareholders, of Eli Lilly and Company at the time of their initial work on this project, and declare no other competing interests. A.K., D.R.W., S.J.D., S.P., and D.R. hold a US patent (#11319370). M.L. is an investigator for AbbVie, Aclaris Therapeutics, Alfasigma, Almirall, Alumis, AnaptysBio, Arcutis Biotherapeutics, Arena Pharmaceuticals, Asana BioSciences, AstraZeneca, BELLUS Health, Boehringer Ingelheim, Brickell Biotech, Bristol Myers Squibb, Cara Therapeutics, Dermavant Sciences, Dermira, Eli Lilly and Company, Foamix Pharmaceuticals, Galderma, Incyte, Janssen, LEO Pharma, Pfizer, RAPT Therapeutics, Sun Pharma, and UCB.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4082"}}